Five new projects supported by our Foundation
In June 2023, our corporate Foundation and its Endowment Fund supported Clubhouse Lyon, Cheer Up !, Dans les pas du hérisson, Night Light and Les enfants de la balle
In June 2023, our corporate Foundation and its Endowment Fund supported Clubhouse Lyon, Cheer Up !, Dans les pas du hérisson, Night Light and Les enfants de la balle
First drinkable formulation of temozolomide for treatment of relapsed or refractory neuroblastom
Dr. Lucy METAYER, co-investigator and pediatric oncologist at the Gustave Roussy will present the results from the pediatric TEMOkids trial on October 14, 2023 during the oral session entitled “novel therapeutic approaches” at the 55th SIOP annual congress to be held in Ottawa, Canada.
Jeremy Bastid, Chief Development Officer at ORPHELIA Pharma will attend the SIOPEN annual general meeting.
The SIOPEN annual meeting brings together about 200 clinicians, investigators, researchers and patient advocates from 34 European countries to discuss on-going clinical trials, results, and work in progress in the field of neuroblastoma.
The following pages will tell you all about the latest projects supported by the Foundation
In June 2023, our corporate Foundation and its Endowment Fund supported Audition Solidarité, Génération avant-garde, Fratries and Afuté
Jeremy Bastid, Chief Development Officer at ORPHELIA Pharma will attend the Advances in Neuroblastoma Research (ANR) meeting to be held May 15-18, 2023 in Amsterdam, the Netherlands.
We are pleased to announce that Jeremy Bastid, Chief Development Officer, and Hugues Bienaymé, General Manager and Chief Scientific Officer at ORPHELIA Pharma, will attend SIOP Europe 2023. We will be present at booth #10 located near the entrance doors to Auditorium 1.